Article
Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.
Current medicinal chemistry - 1 Jan 2019
Hahn Roberta Zilles, Antunes Marina Venzon, Verza Simone Gasparin, Perassolo Magda Susana, Suyenaga Edna Sayuri, Schwartsmann Gilberto, Linden Rafael
Abstract excerpt
BACKGROUND: Irinotecan (IRI) is a widely used chemotherapeutic drug, mostly used for first-line treatment of colorectal and pancreatic cancer. IRI doses are usually established based on patient's body surface area, an approach associated with large inter-individual variability in drug exposure and high incidence of severe toxicity. Toxic and therapeutic effects of IRI are also due to its active metabolite SN-38,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.